Research progress on interventional surgery containing raltitrexed chemotherapy regimen in the treatment of intermediate and advanced hepatocellular carcinoma
Hepatocellular carcinoma(HCC)is the most common type of primary liver cancer.Due to the chal-lenges in early detection,many patients are diagnosed at intermediate to advanced stages without potential chance of radical surgery.Interventional surgery has emerged as an effective treatment for unresectable HCC in the mid-to-late stages,primarily including two approaches:transcatheter arterial chemoembolization(TACE)and hepatic arterial infu-sion chemotherapy(HAIC).Nevertheless,further exploration is needed on which chemotherapy drugs should be used in interventional surgery.Several clinical studies have demonstrated the beneficial effects of interventional surgery in-corporating raltitrexed chemotherapy in local and regional treatment settings.However,the optimal timing,efficacy,and safety of raltitrexed in interventional chemotherapy for HCC diagnosis and treatment remain uncertain,necessitat-ing large-scale,prospective,multi-center clinical trials for additional research and validation.This article reviews the application of interventional surgery combined with raltitrexed chemotherapy in the treatment of mid-to-late HCC.
万方数据
维普
